The British pharmaceutical company Astrazeneca announced on Monday that its anti-Covid-19 vaccine Vaxzevria had been approved as a 3rd dose for adults in the European Union (EU).
“Healthcare professionals can now use Vaxzevria as a third dose in patients who have previously received doses of Vaxzevria or an EU-approved messenger RNA vaccine.” The European Medicines Agency gave clearance on Thursday “following a sufficient body of evidence demonstrating an increase in immune response following a third dose of Vaxzevria” following two doses of Astrazeneca’s vaccine or another approved in EU, according to a statement on the agency’s website.
The pharmaceutical giant saw its sales jump in the first quarter, in particular thanks to drugs or vaccines linked to Covid-19, but said it expected a sharp drop in sales of these drugs over the rest of the year as “the threat of Covid-19 recedes”.
The vaccine created in collaboration with the University of Oxford was not chosen by the British government for its recall campaign although it had been one of the first on the market and had been favored for the first two doses campaign in the UK. It is also not approved in the United States.
The British pharmaceutical company Astrazeneca announced on Monday that its anti-Covid-19 vaccine Vaxzevria had been approved as a 3rd dose for adults in the European Union (EU).
“Healthcare professionals can now use Vaxzevria as a third dose in patients who have previously received doses of Vaxzevria or an approved messenger RNA vaccine in…
